Stocktoria
Eton Pharmaceuticals, Inc. ETON
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-11-09
Eton Pharmaceuticals, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 53.5% | 60.0% | 66.6% | 67.4% | 87.1% |
| Operating margin | -1.1% | -6.7% | -3.8% | -38.9% | -6.8% |
| Net margin | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% |
| FCF margin | 12.7% | 2.4% | 21.5% | 22.5% | -21.7% |
| Return on assets | -5.0% | -5.0% | -2.9% | -36.0% | -7.1% |
| Return on equity | -17.6% | -15.7% | -6.0% | -69.0% | -11.1% |
| Debt / equity | 0.83× | 1.22× | 0.00× | 0.41× | 0.30× |
| Current ratio | 1.57 | 2.06 | 1.65 | 3.10 | 5.18 |
| Revenue growth | 104.9% | 23.3% | 48.9% | -2.7% | 55879.5% |
Source: SEC EDGAR filings · CIK 0001710340 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.